HOME >> BIOLOGY >> NEWS
Deserts and rainforests are equally productive during drought

New Haven, Conn. A team of researchers led by Melinda Smith at Yale and Travis Huxman at the University of Arizona report that, from desert to rainforest, during drought conditions, the maximum rain use efficiency (RUEmax), or effective productivity of plant growth per unit of precipitation converges to a common value.

During the late 1960s and early 1970s, the International Biological Program (IBP) began to study how water affects productivity in different ecosystems. It was not until this current group of scientists pooled long-term data in a workshop at the National Center for Ecological Analysis and Synthesis at University of California, Santa Barbara that the scope and similarity of productivity in all ecosystems was seen. Their study, published in the journal Nature, represents datasets from 14 ecosystems.

The RUEmax model predicts that when water is the most limiting resource there will be convergence in the production-precipitation ratio for all biomes. The previous, site model predicts there will be a difference in productivity and that sensitivity of different ecosystems is a function of the different forms of plant growth.

"We looked across nine different biomes - from a forest all the way to a very dry desert - at the sensitivity of production to precipitation," said Smith, associate professor of Ecology and Evolutionary Biology at Yale. "The data showed that if you look at the driest year, when water is most limiting, in any of the 14 sites - and compare growth production in that year - the rate of growth production in all biomes converges to a RUEmax that is very similar to what is seen in deserts."

Therefore, in a forest, during a really dry year there is the same growth production per unit of precipitation as there is in a really dry year in a desert. This data indicates that production sensitivity depends on the extent to which water is the limiting resource.

Although the RUEmax model is based on previou
'"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
29-Jun-2004


Page: 1 2 3

Related biology news :

1. Duke Ecologist Says Logging Is Creating Mahogany Deserts
2. A realistic way to save rainforests
3. Weeds in disturbed areas may be source of more medically important compounds than plants in tropical rainforests
4. Biologists work to preserve rainforests endangered plants
5. Endurance exercise found to be equally effective as diuretics in improving cardiac health
6. All ecosystems are equally productive under drought conditions
7. Study shows that aspirin and warfarin are equally effective for stroke prevention
8. The birth of reproductive health: A difficult delivery
9. Stem-cell research and reproductive cloning laws should be separate
10. Germans must research the history of reproductive medicine during the Nazi era
11. $5 million grant funds partnership, studies of minority-based issues in reproductive health

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Deserts and rainforests are equally productive during drought

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: